A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11709-11717

  Goldberg, Liat ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; FARNESYLTHIOSALICYLIC ACID; GUANOSINE TRIPHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAC PROTEIN; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; FOCAL ADHESION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMOBILIZED CELL; MATRIX ATTACHMENT REGION; PRIORITY JOURNAL; STRESS FIBER;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; RAC GTP-BINDING PROTEINS; RHO GTP-BINDING PROTEINS;

EID: 33846205171     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1878     Document Type: Article

References (44)

1. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-9.
2. Markert J. Glioblastoma multiforme: introduction. Cancer J 2003;9:148.
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36.
4. Haklai R, Gana-Weisz M, Elad G, et al. Dislodgment and accelerated degradation of Ras. Biochemistry 1998;37:1306-14.
5. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-54.
6. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001;276:15609-15.
7. Joneson T, White MA, Wigler MH, Bar Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 1996;271:810-2.
8. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
9. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998;273:19925-8.
10. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994;264:1463-7.
11. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994;369:411-4.
12. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
13. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
14. Wolthuis RM, Bos JL. Ras caught in another affair: the exchange factors for Ral. Curr Opin Genet Dev 1999;9:112-7.
15. Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003;13:419-25.
16. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005;33:891-5.
17. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
18. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997;15:2755-65.
19. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death. Cancer Res 2005;65:999-1006.
20. Blum R, Nakdimon I, Goldberg L, Shamir R, Rechavi G, Kloog Y. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer 2006;119:527-38.
21. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 1995;38:1267-72.
22. Etienne-Manneville S. In vitro assay of primary astrocyte migration as a tool to study Rho GTPase function in cell polarization. Methods Enzymol 2006;406:565-78.
23. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997;14:623-5.
24. Wolthuis RM, Franke B, van Triest M, et al. Activation of the small GTPase Ral in platelets. Mol Cell Biol 1998;18:2486-91.
25. Benard V, Bohl BP, Bokoch GM. Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem 1999;274:13198-204.
26. Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 2006;66:3153-61.
27. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 2006;5:2337-47.
28. Shalom-Feuerstein R, Lindenboim L, Stein R, Cox AD, Kloog Y. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor. Cell Death Differ 2004;11:244-7.
29. Lambert JM, Lambert QT, Reuther GW, et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002;4:621-5.
30. Scita G, Nordstrom J, Carbone R, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature 1999;401:290-3.
31. Park SH, Weinberg RA. A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. Oncogene 1995;11:2349-55.
32. Salhia B, Rutten F, Nakada M, et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 2005;65:8792-800.
33. Rottner K, Hall A, Small JV. Interplay between Rac and Rho in the control of substrate contact dynamics. Curr Biol 1999;9:640-8.
34. Moorman JP, Luu D, Wickham J, Bobak DA, Hahn CS. A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene 1999;18:47-57.
35. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999;285:895-8.
36. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004;265:23-32.
37. Saunders RM, Holt MR, Jennings L, et al. Role of vinculin in regulating focal adhesion turnover. Eur J Cell Biol 2006;185:487-500.
38. Hamadi A, Bouali M, Dontenwill M, Stoeckel H, Takeda K, Ronde P. Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397. J Cell Sci 2005;118:4415-25.
39. Hwang SY, Jung JW, Jeong JS, et al. Dominant-negative Rac increases both inherent and ionizing radiation-induced cell migration in C6 rat glioma cells. Int J Cancer 2006;118:2056-63.
40. Blum R, Kloog Y. Tailoring Ras-pathway-inhibitor combinations fo cancer therapy. Drug Resist Updat 2005;8:369-80.
41. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7:17-23.
42. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005;11:4321-30.
43. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma J Clin Oncol 2006;24:1253-65.
44. Shohami E, Yatsiv I, Alexandrovich A, et al. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model. J Cereb Blood Flow Metab 2003;23:728-38.